Folic acid nudges one inflammation marker down, and leaves two others untouched

Chronic low-grade inflammation sits behind a long list of health concerns, which is why blood markers like C-reactive protein, IL-6 and TNF-α attract so much attention. Folic acid, a cheap and widely taken B vitamin, has long been theorised to improve inflammation. The trouble is that individual clinical studies testing this idea have produced inconsistent results, leaving readers and clinicians unsure whether the supplement does anything measurable. Pooling the trials is the obvious way to settle the disagreement, and that is exactly what this review set out to do.

The researchers ran a systematic search up to April 2021 across PubMed/Medline, Scopus, Web of Science, EMBASE, the Cochrane databases and Google Scholar to find randomised controlled trials of folic acid supplementation. Twelve trials met the criteria and were pooled in a meta-analysis. The team calculated weighted mean differences between folic acid and placebo for three inflammatory markers: C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. They also ran a dose-response analysis to test whether larger doses produced larger changes.

Folic acid significantly reduced serum CRP compared with placebo, by 0.59 mg/L on average, with a confidence interval running from 0.85 to 0.33 mg/L below placebo. The dose-response analysis showed a significant relationship between higher folic acid doses and lower CRP concentrations. The other two markers told a different story: IL-6 and TNF-α showed no significant change, with pooled differences close to zero. So the anti-inflammatory effect, such as it is, appears confined to one marker rather than reflecting a broad dampening of inflammation.

This analysis partially supports the theory that folic acid improves inflammation, but only partially. Earlier individual trials had pointed in different directions, and this pooling suggests the true effect is real for CRP yet absent for IL-6 and TNF-α. The authors are open about the limits: the number of included trials is small, and they call for future randomised trials with more participants and more diverse populations to confirm and expand the findings. Whether marker changes of this size matter for actual health outcomes remains an open question.

If you take folic acid, this is a reason to think it may nudge one inflammatory marker downwards, and the effect appears to grow with dose across the included trials. It is not a reason to think folic acid broadly switches off inflammation, since two of the three markers measured did not respond at all. It is also not evidence about disease outcomes: nobody here measured heart attacks, joint pain or anything a person would feel. The honest reading is a modest, marker-specific effect awaiting confirmation in larger trials.